Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Uy Ear
MIZU
Uy Ear
Mizuho Securities
Wall Street Analyst
★★★★☆
#372
on 13Foresight · ranked by our own returns
67%
Success Rate
+10.0%
Average Return
14 of 21 calls profitable · +5.7% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 67% of Uy Ear's ratings turned a profit when each position was held for 1 year — averaging +10.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

107 Buy 14 Hold 0 Sell
Uy's Stock Coverage 16 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
MBX
MBX Biosciences, Inc.
 Jun 12, 2026 BUY Strong Buy
+54.0% avg upside
14 analysts
$57.00
38.88% Upside
 +12.9%
TECX
Tectonic Therapeutic
 Jun 10, 2026 BUY Strong Buy
+88.0% avg upside
24 analysts
$85.00
183.59% Upside
 ·
RNAC
Cartesian Therapeutics
 Jun 09, 2026 BUY Strong Buy
+228.5% avg upside
19 analysts
$40.00
319.21% Upside
 +0.0%
ALKS
Alkermes
 Jun 09, 2026 BUY Strong Buy
-17.5% avg upside
34 analysts
$53.00
20.09% Upside
 +2.4%
EOLS
Evolus
 Jun 08, 2026 BUY Strong Buy
+116.3% avg upside
9 analysts
$15.00
126.67% Upside
 +0.9%
ARQT
Arcutis Biotherapeutics
 Jun 03, 2026 BUY Strong Buy
+49.8% avg upside
14 analysts
$35.00
35.93% Upside
 +20.2%
INAB
IN8bio
 Jun 01, 2026 BUY Strong Buy
+4095.8% avg upside
5 analysts
$4.00
179.81% Upside
 ·
RLMD
Relmada Therapeutics
 May 14, 2026 BUY Buy
+106.4% avg upside
15 analysts
$19.00
188.35% Upside
 -14.1%
ACAD
ACADIA Pharmaceuticals
 May 07, 2026 BUY Strong Buy
+66.0% avg upside
42 analysts
$35.00
62.15% Upside
 -4.3%
SRPT
Sarepta Therapeutics
 May 06, 2026 BUY Buy
+246.5% avg upside
49 analysts
$31.00
74.68% Upside
 -31.6%
QURE
uniQure
 May 05, 2026 BUY Strong Buy
+16.1% avg upside
29 analysts
$35.00
24.71% Downside
 +16.8%
NBIX
Neurocrine
 Dec 12, 2025 HOLD Strong Buy
+7.8% avg upside
37 analysts
$175.00
11.43% Upside
 +4.5%
OCGN
Ocugen
 Aug 18, 2023 HOLD Strong Buy
+645.9% avg upside
17 analysts
 — +180.5%
CABA
Cabaletta Bio
 Aug 11, 2023 HOLD Strong Buy
+390.0% avg upside
16 analysts
 — -69.5%
TEVA
Teva Pharmaceutical
 Jul 10, 2019 HOLD Buy
-6.8% avg upside
39 analysts
$14.00
55.01% Downside
 +28.1%
IRWD
Ironwood Pharma
 Jul 10, 2019 HOLD Hold
+235.8% avg upside
23 analysts
$14.00
297.19% Upside
 -6.7%
🔒 11 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Uy Ear — Frequently Asked Questions
How accurate are Uy Ear's stock ratings?
Based on the calls 13Foresight could measure, about 67% of Uy's ratings were profitable over a one-year hold, with an average return of +10.0% per rating, or +6.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Uy ranked on 13Foresight?
Uy Ear is currently ranked #372 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Uy cover?
Uy most recently has ratings on MBX, TECX, RNAC, ALKS, EOLS, ARQT, INAB, RLMD, ACAD, SRPT, QURE, NBIX and 4 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.